| Article Access Statistics | | | Viewed | 33598 | | | Printed | 577 | | | Emailed | 0 | | | PDF Downloaded | 38 | | | Comments | [Add] | | | Cited by others | 53 | | |
|
Click on image for details.
|
|
 |
| REVIEW ARTICLE |
|
|
|
| Year : 2017 | Volume
: 63
| Issue : 4 | Page : 242-251 |
Ketogenic diet in endocrine disorders: Current perspectives
L Gupta1, D Khandelwal2, S Kalra3, P Gupta4, D Dutta5, S Aggarwal6
1 Department of Dietetics, Maharaja Agrasen Hospital, New Delhi, India
2 Department of Endocrinology, Maharaja Agrasen Hospital, New Delhi, India
3 Department of Endocrinology, Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology, Karnal, Haryana, India
4 Department of Paediatrics, Maharaja Agrasen Hospital, New Delhi, India
5 Department of Endocrinology, Venkateshwar Hospitals, New Delhi, India
6 Department of Medicine, Division of Endocrinology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India
| Date of Submission | 07-Jan-2017 |
| Date of Decision | 15-Apr-2017 |
| Date of Acceptance | 12-Aug-2017 |
| Date of Web Publication | 11-Oct-2017 |
Correspondence Address:
S Kalra
Department of Endocrinology, Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology, Karnal, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpgm.JPGM_16_17
Ketogenic diet (KD) is a high-fat, adequate-protein, and low-carbohydrate diet that leads to nutritional ketosis, long known for antiepileptic effects and has been used therapeutically to treat refractory epilepsy. This review attempts to summarize the evidence and clinical application of KD in diabetes, obesity, and other endocrine disorders. KD is usually animal protein based. An empiric vegetarian Indian variant of KD has been provided keeping in mind the Indian food habits. KD has beneficial effects on cardiac ischemic preconditioning, improves oxygenation in patients with respiratory failure, improves glycemic control in diabetics, is associated with significant weight loss, and has a beneficial impact on polycystic ovarian syndrome. Multivitamin supplementations are recommended with KD. Recently, ketones are being proposed as super-metabolic fuel; and KD is currently regarded as apt dietary therapy for “diabesity.”
Keywords: Diabetes, epilepsy, ketogenic diet, metabolic syndrome, nutritional ketosis, obesity, polycystic ovary syndrome
How to cite this article:
Gupta L, Khandelwal D, Kalra S, Gupta P, Dutta D, Aggarwal S. Ketogenic diet in endocrine disorders: Current perspectives. J Postgrad Med 2017;63:242-51 |
How to cite this URL:
Gupta L, Khandelwal D, Kalra S, Gupta P, Dutta D, Aggarwal S. Ketogenic diet in endocrine disorders: Current perspectives. J Postgrad Med [serial online] 2017 [cited 2023 Jun 4];63:242-51. Available from: https://www.jpgmonline.com/text.asp?2017/63/4/242/216437 |
| :: Introduction | |  |
The ketogenic diet (KD) is described as a high-fat, adequate-protein, and low-carbohydrate diet. With the inadequate availability of carbohydrates, the body burns fats rather than carbohydrates to provide energy. The liver converts fat into fatty acids and produces ketone bodies (KB), which replace glucose as a primary energy source. This dietary accumulation of ketones in blood is also known as nutritional ketosis (NK).[1]
Since the introduction of KD in 1920, research has emerged to understand its mechanisms and uses in various clinical conditions. Because of its pleiotropic effects on central nervous system, cellular metabolism and metabolic pathways, KD has been studied and has shown promising results in variety of neurological disorders, traumatic brain injury, acne, cancers, and metabolic disorders [Table 1].[2],[3],[4],[5],[6],[7] Recently, ketones have been proposed as super-metabolic fuel because of their various favorable impacts on cellular metabolism in many tissues.
This review is an attempt to summarize the evidence of KD in diabetes, obesity, and other endocrine disorders. We have also focused on application of KD in clinical practice, its benefits, as well as the cautions and contraindications to its use.
| :: Physiology of Ketogenic Diet | | |
Glucose and fatty acids are metabolized to acetyl coenzyme A (CoA) (a product of incomplete breakdown of free fatty acids [FFAs] in the liver) to enter the citric acid cycle (tricarboxylic acid cycle) by condensing with oxaloacetate (pyruvate being precursor). As glycolysis falls to very low levels with KD because of low carbohydrates, oxaloacetate is not available to condense with acetyl-CoA produced by fatty acid metabolism. This leads to shunting of acetyl CoA to ketogenesis and results in accumulation of ketones.[8] KB synthesized in the body are β-hydroxybutyrate (βOHB), acetoacetate, and acetone, which can also cross the blood–brain barrier to provide an alternative source of energy for the brain. Heart, muscle, and renal cortex can easily utilize KB while brain utilizes ketones only in prolonged starvation. Erythrocytes do not utilize ketones as they do not have mitochondria. Liver does not utilize ketones as it does not have the enzyme thiophorase.[9]
Ketone build-up in a particular individual depends on several physiological parameters such as body fat percentage, body mass index (BMI), and resting metabolic rate.[1] The KD should ideally be administered under controlled environment. KD is quite safe as the concentration of ketones in persons on KD is far lower than the concentration seen in diabetic ketoacidosis and is not associated with any changes in blood pH. It must be mentioned here that human nutrition begins with a KD: Colostrum is ketogenic and serves the needs of the neonate completely.[10]
It is proposed that such diet may favor more fat loss with preservation of lean body mass. This effect is partly mediated by reduced plasma insulin levels.[11],[12] Risk of lean body mass loss and sarcopenia can prevented with judicious supplementation of amino acids and whey protein.[13],[14] Studies have shown induction of fibroblast growth factor-1 (FGF-1) gene by KD. FGF-1 acts as a metabolic regulator of lipolysis, serum phosphate, active Vitamin D level, and triglyceride clearance in the liver.[15],[16]
| :: Beneficial Impacts of Ketogenic Diet | | |
KB as “super-fuel” efficiently produce more adenosine triphosphate (ATP) energy than glucose or fatty acids by reducing the mitochondrial nicotinamide adenine dinucleotide couple and oxidizing the coenzyme Q couple. 100 g of acetoacetate is able to generate 9.4 kg ATP and 100 g of 3-hydroxybutyrate yields 10.5 kg ATP while 100 g glucose produces only 8.7 kg ATP. This allows the body to maintain efficient fuel production in the face of calorie loss.[10] KB also decreases free radical damage and enhances antioxidant capacity by activation of NF E2-related factor 2, which upregulates transcription of genes involved in protection against oxidative damage.
Impact on central nervous system
There are studies supporting possible therapeutic utilization of KD in multiple neurological disorders. Potential mechanism could be neuroprotective effect by modulation in cellular energy utilization. NK has shown to improve physical and cognitive performance, improve cerebral function, and prolong survival in anoxic rats and mice. It also improves posttraumatic metabolism in man.[17] KD is considered an established part of an integrative approach, along with drug therapy, in major epilepsy centers worldwide. The bioenergetic transition from glucose to KB can metabolically target brain tumors through integrated anti-inflammatory pathways/mechanisms. Enhanced phagocytic activities of macrophages, antiangiogenic, and pro-apoptotic mechanisms reduce tumor energy metabolism and glycolytic energy required for tumor growth.[18]
Impact on heart
The cardiac muscle is an “omnivore,” which uses diverse substrates as sources of fuel, preferring FFAs, followed by glucose, KB, lactate, pyruvate, glycogen, and amino acids. NK results in shift of myocardial fuel metabolism from fat/glucose oxidation to more energy-efficient fuel KB and improves myocardial work efficiency and function.[10] The failing heart facilitates fuel metabolic shift to KB for oxidative ATP production triggered by reduced capacity for oxidizing fatty acids (the chief fuel for the normal adult mammalian heart). It attenuates free radical induced injury, improves energy reserves of the heart, increases the acetyl-CoA content of the myocardium, and improves the transduction of oxygen consumption into work efficiency at the mitochondrial level in the endangered myocardium and thereby enhancing myocardial metabolism.[19],[20] Studies have shown that it prevents ischemic tissue damage in animal models undergoing either myocardial infarctions or stroke, leading to dramatically smaller ischemic/necrotic lesion area.[21],[22] Electron microscopic studies show an increase in the number of mitochondria, tolerance to ischemia, and a faster recovery of cardiac function following reperfusion in rats fed with KD; hence, it is cardioprotective.[23]
Impact on respiratory system
KD decreases the need for glucose synthesis in liver and spares its precursor, muscle-derived amino acids, and diminishes apoptosis in lung cells in shocked rodents. It decreases the death of lung cells induced by hemorrhagic shock. Moreover, it is beneficial in respiratory problems with limited oxygen supply or substrate utilization.[17] It may decrease respiratory exchange ratio, carbon dioxide output, and carbon dioxide end-tidal partial pressure which proves beneficial for patients with increased arterial carbon dioxide partial pressure due to respiratory insufficiency or failure.[24]
| :: Use of Ketogenic Diet | | |
This section describes patient selection, pre-KD counseling and evaluation, implementation of KD, supplementation, follow-up/monitoring, and eventual KD discontinuation.
Patient selection and preketogenic diet assessment
The pre-KD assessment requires detailed history and physical examination, specific laboratory tests, nutritional assessment, and counseling of the patient and family members. Some patients with specific metabolic disorders may have absolute contraindications to start KD. In addition, complicating risk factors (renal stones, severe dyslipidemia, significant liver disease, failure to thrive, severe gastroesophageal reflux, poor oral intake, cardiomyopathy, and chronic metabolic acidosis) may prevent initiation of KD.[25]
Lot of therapeutic medications including many anticonvulsants may have high carbohydrate content and should be switched to lower carbohydrate preparations if option is available. Patients should be started on multivitamins containing adequate doses of essential minerals as well as calcium supplements before initiation of KD.[26]
Application
The planning of KD requires diet instructions to lower the intake of carbohydrates to <20 g/day, increase the intake of fats/oils, and include nutritional supplements to maintain the calorie requirement of the individual. The total amount of calories to be provided for a particular individual is based on anthropometric measurements, prior dietary intake, and physical activity. The various menu options are discussed in [Table 2]. The diet should be modified if the patient has poor dietary tolerability and frequent gastrointestinal symptoms.[25],[26],[27],[28],[29],[30],[31],[32]
KD involves flexibility to use long-chain triglycerides (LCT) or medium chain triglycerides (MCT). Omega-3 supplementation has its own positive effects.[33] Fat rich diet is prescribed with low-carbohydrate fruits and vegetables in each meal. Home-based diets (with the addition of a liquid fat source, and micronutrients supplementation) as well as commercial formulas (KetoCal, Ross Carbohydrate FreeSoy Formula Base with Iron) may be used.[25],[26]
Fluid restriction is not required and also individuals may be motivated to continue routine exercises. The carbohydrate-free or minimal carbohydrate-containing multivitamins and multimineral preparations should be administered to prevent nutritional deficiencies. Nutrients significantly required with KD are calcium with Vitamin D, selenium, magnesium, zinc, and phosphorus.[29] Evaluation of the diet should be done periodically to monitor the beneficial effects and associated risks.
Monitoring urine ketones is necessary to ensure that the diet is being managed correctly. It is generally advisable that patients on KD should monitor their serum glucose, albumin, total protein, total cholesterol, triglycerides, and serum creatinine once in every 3 months. Once a year, renal ultrasound, bone density, carnitine, selenium levels, and electrocardiogram are significant with regard to the prevention of long-term effects such as nephrolithiasis, osteoporosis, hyperlipidemia, carnitine deficiency, and cardiomyopathy.
Although very low carbohydrate KD was proved to be safe and effective in morbidly obese patients scheduled for laparoscopic bariatric surgery, there is a scarcity of data on KDs being used for prebariatric surgery management of morbid obesity. Most research support the use of restricted energy diets for preoperative weight loss evidenced to reduce the risk of postoperative complications, reduce liver volume, and fat content in obese patients to improve patient outcome.
Postketogenic diet assessment
The diet can be discontinued abruptly in an emergency but is more often tapered slowly over 2–3 months by gradually lowering the ketogenic ratio from 4:1–3:1–2:1. Calories and fluids are increased ad libitum, and larger amounts of carbohydrate foods and nutritional supplements are reintroduced with loss of urinary ketones.[25]
| :: Evidence of Ketogenic Diet in Endocrine Disorders | | |
The favorable effects of KD on caloric intake, body weight, lipid parameters, glycemic indices, and insulin sensitivity render it a therapeutic option in metabolic syndrome, obesity, and obese type 2 diabetes. Various hormones such as insulin, glucagon, cortisol, catecholamines, and growth hormone also significantly affect ketone-body metabolism.[34]
Diabetes
A variety of dietary modifications has been studied to improve glycemic control such as low calorie diet, low-fat diet, low-protein diet, high-protein diet, and low glycemic load diet.[35] Since the dietary carbohydrate is the major macronutrient that raises the blood glucose levels, researchers have aimed to reduce the amount of carbohydrate in the meals to study the effects on glycemic load, antidiabetic regimen, and drug dosage among diabetic people. Dietary carbohydrate restriction reliably reduces high blood glucose, does not require weight loss (although is still best for weight loss), and leads to the reduction or elimination of medication.[28],[36] Studies of KD looking into benefit on glycemic indices and other metabolic parameters in patients with type 2 diabetes are summarized in [Table 3].[28],[37],[38],[39],[40]
The analysis of the KD map from the diabetes perspective identifies strong relationship between the insulin resistance pathway and KD. It highlights that elements of lipid metabolism may facilitate proper cellular localization of glucose transporters, recycling, and KB can alleviate certain inflammatory processes by blocking specific cytokines.[28],[36] With the increased plasma ketones, there is decreased plasma glucose, decreased cerebral metabolic rate of glucose (CMRglc), and increased cerebral metabolic rate of acetoacetate (CMRa).[41] In obese patients with type 2 DM, high-ketogenic VLED treatment lowers fasting, OGTT glycemia, and improves glycemic control.[40],[42] High-protein, low-carbohydrate KD reduces hunger, and lowers food intake.[43] KD are significantly beneficial in improve glycemic control (glycated hemoglobin), eliminate/reduce diabetic medications, increase high-density lipoprotein-cholesterol (HDL-C), and cause weight loss in overweight and obese individuals with type 2 diabetes over a 24-week period compared to low glycemic index diet.[39],[44] Moreover, limiting both protein and carbohydrates in KD reverses diabetic nephropathy.[45] However, such diet may not benefit in preventing the decline in β-cell function and may not improve the insulin secretory function or β-cell mass.[46]
Sodium glucose cotransporter 2 (SGLT2) inhibitors, especially empagliflozin and canagliflozin, has been shown to have cardiovascular benefits in patients with type 2 diabetes. SGLT 2 inhibitors also exhibit pro-ketogenic effects by mediating a metabolic switch from glucose to lipid utilization. As a class they increase the production of KB in the liver, by increasing glucagon levels and reducing the insulin: glucagon ratio. One of the postulated mechanisms behind their exceptional cardiovascular and renal benefits in patients with type 2 diabetes is likely because of mild ketosis with these drugs, resulting in improvement of peripheral insulin sensitivity, reducing hyperinsulinemic stress, and inherent insulin secretion with lowered requirement for external insulin. Mild ketosis also has beneficial effects on the myocardial metabolism, for the failing diabetic heart. However, patients with type 2 diabetes who are already receiving SGLT2 inhibitors, have significantly higher risk of developing euglycemic diabetic ketoacidosis if put on low carbohydrate KD; hence, KD should not be prescribed to patients with type 2 diabetes on SGLT2 inhibitors.[10]
Among patients with diabetes, carbohydrate restriction may increase the risk of hypoglycemia, especially in patients treated with insulin and insulin secretagogues (sulfonylureas, incretin-based therapies). Hence, modification in drug dosage is recommended before initiating such diet depending on glycemic control and class of antidiabetes medication therapy.[47]
Obesity
In obese patients, KD treatment had shown greater weight loss as compared to other balanced diets. This comparative greater weight loss makes it an alternative tool against obesity.[48],[49],[50] The possible mechanisms for higher weight loss may be controlled hunger due to higher satiety effect of proteins, direct appetite suppressant action of KB, and changes in circulating the level of several hormones such as ghrelin and leptin which controls appetite.[51],[52] Other mechanisms proposed are reduced lipogenesis, increased lipolysis, reduction in resting respiratory quotient, increased metabolic costs of gluconeogenesis, and the thermic effect of proteins.[53],[54]
A study conducted by Castaldo et al. in 2016 shows that short-term ketogenic EN followed by an almost carbohydrate-free oral nutrition may effectively reduce body weight, waist circumference, blood pressure, and insulin resistance in clinically healthy morbidly obese adults (BMI ≥45 kg/m 2).[55] The diet significantly decreases cholesterol, blood glucose, body weight, BMI, and thereby reducing risk factors for various chronic diseases among obese hypercholesterolemic patients (BMI >35 kg/m 2) without any side effects in long term.[56]
Metabolic syndrome
Insulin resistance in peripheral tissues manifests as hyperglycemia, hyperinsulinemia, abnormal fatty acid metabolism and atherogenic dyslipidemia in MetS, and cardiovascular diseases. Dietary carbohydrate modulates lipolysis, assembly, and processing of lipoprotein.[47],[57] KD in long term (12 months or more) results in decreased body weight, triglycerides, and diastolic blood pressure whereas it causes increased HDL-C and low-density lipoprotein-C as compared to low fat diet.[53],[58]
The elevated plasma βOHB correlates with decreased plasma cholesterol, mevalonate (a liver cholesterol synthesis biomarker) and lower levels of the mevalonate precursors acetoacetyl-CoA and 3-hydroxy-3-methylglutaryl-CoA in liver. Increased βOHB promotes a nonatherogenic lipid profile, improves cardiovascular risk parameters, lowers blood pressure, diminishes resistance to insulin, without any adverse impact on renal or liver functions.[59],[60]
Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is associated with obesity, hyperinsulinemia, insulin resistance, reproductive and metabolic implications. The metabolic and endocrine effects of low carbohydrate KD are evidenced by improvements in body weight, free testosterone percentage, luteinizing hormone/follicle-stimulating hormone ratio, and fasting insulin levels. It leads to decrease in androgen secretion and increase in sex-hormone binding globulin, improves insulin sensitivity and thereby renormalizes endocrine functions. Such dietary intervention and lifestyle management has beneficial effects in the treatment of PCOS patients affected with obesity and type 2 diabetes.[61],[62],[63] It has also been shown to improve depressive symptoms, psychological disturbances, and health-related quality of life in these patients.[64]
The detailed discussion of KD in nonendocrine disorders is outside the scope of this review. The possible disease specific modifying effects of KD in nonendocrine disorders are summarized in [Table 4].[3],[65],[66],[67],[68],[69],[70],[71] | Table 4: Disease specific modifying effects of ketogenic diet in nonendocrine disorders
Click here to view |
| :: Adverse Effects | | |
Adverse effects can be classified either as mild, moderate, and severe or short term and long term [Table 5].[72],[73] Common adverse effects are mild and include headache, constipation, diarrhea, insomnia, and backache. High level of MCTs in KD may cause gastrointestinal discomfort with reports of abdominal cramps, diarrhea, and vomiting.[25] The moderate adverse effects comprised of dyslipidemia, mineral deficiencies, metabolic acidosis, and increased risk of renal stones. It may lead to increased triglycerides within a period of 6 months.[73],[74] Hypoproteinemia is also commonly observed; which could be due to associated reduced protein intake.[75] The severe effects are associated with elevated levels of ketones that can lead to complications by increasing redox imbalance and thereby risk of morbidity and mortality in diabetic patients.[76] With regard to possible acidosis during KD, as the concentration of KBs never rises above 8 mmol/L, this risk is virtually nonexistent in subjects with normal insulin function.
Long-term KD causes glucose intolerance associated with insufficient insulin secretion, insulin resistance, and reduced beta and alpha cell mass in mice (the long-term effects on pancreatic endocrine cells).[77] There are risks of more visceral and bone marrow fat, increased leptin, decreased insulin-like growth-factor 1, reduced bone mineral density, reduced transcription factors promoting osteoblastogenesis, and hence, reduced bone formation.[78] Plasma markers associated with dyslipidemia and inflammation (cholesterol, triglycerides, leptin, monocyte chemotactic protein-1, Interleukin [IL]-1, and IL-6) were increased, and KD-fed mice showed signs of hepatic steatosis after 22 weeks of KD.[77]
Some of the adverse effects may be preventable and easily treatable such as dehydration, hypoglycemia, and mild acidosis. Less quantity of MCT combined with LCT and increased meal frequency may improve diet tolerance.[25] Supplements of calcium, selenium, zinc, vitamin D, and oral alkalis are prescribed to reduce the incidence of nutritional deficiencies and kidney stones.[66] H2-blockers or proton pump inhibitors may be prescribed to prevent gastrointestinal dysmotility and gastroesophageal reflux.[25] In addition, high-fiber vegetables, sufficient fluids, and if necessary, carbohydrate-free laxatives are recommended to overcome constipation.
| :: Cautions and Contraindications | | |
The metabolic adaptation to the KD involves a shift from use of carbohydrates to lipids as the primary energy source. As such, a patient with a disorder of fat metabolism might develop a devastating catabolic crisis (i.e., coma, death) in the setting of fasting or a KD. Therefore, before initiating the KD, patients must be screened for disorders of fatty acid transport and oxidation, especially for children with seizure disorders and developmental abnormalities. KD is also contraindicated in porphyria (a disorder of heme biosynthesis in which there is deficient porphobilinogen deaminase), and patients with deficiency of pyruvate carboxylase enzyme [25] [Table 6].[10],[79]
Hence, detailed history, physical examination, growth assessment in children and routine laboratory monitoring is indispensible before KD initiation and during follow-up visits. KD should not be advised for diabetic patients on SGLT2 inhibitors, as discussed in the previous section.
| :: Conclusion | | |
There is clinical evidence to support the use of KD in diabetes, obesity, and endocrine disorders. KD is gaining interest but is to be performed under strict medical supervision of dieticians and physicians to be effective and may, therefore, require hospital settings for its initiation. To facilitate the patient acceptability, tolerability, and palatability, the diet protocols are gradually modified including initiation of the diet with or without fasting, regular follow-ups to minimize complications, changes in ratios of the fat versus nonfat components and fatty acids composition. Such diets may positively influence hormonal balance and endocrinological disorders, but future studies are required to assess the long-term effects on health and reversing of diabetic complications in humans. The understanding of clinical impacts, safety, tolerability, efficacy, duration of treatment, and prognosis after discontinuation of the diet is challenging and requires further studies to understand the disease-specific mechanisms.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| :: References | | |
| 1. | Prabhakar A, Quach A, Zhang H, Terrera M, Jackemeyer D, Xian X, et al. Acetone as biomarker for ketosis buildup capability – A study in healthy individuals under combined high fat and starvation diets. Nutr J 2015;14:41.  |
| 2. | Maiorana A, Manganozzi L, Barbetti F, Bernabei S, Gallo G, Cusmai R, et al. Ketogenic diet in a patient with congenital hyperinsulinism: A novel approach to prevent brain damage. Orphanet J Rare Dis 2015;10:120. |
| 3. | Barañano KW, Hartman AL. The ketogenic diet: Uses in epilepsy and other neurologic illnesses. Curr Treat Options Neurol 2008;10:410-9. |
| 4. | Kalra S, Unnikrishnan AG, Gupta Y. Epileptogenicity of diabetes and antiepileptogenicity of ketogenic states: Clarity or confusion? Indian J Endocrinol Metab 2016;20:583-5. |
| 5. | Lee M. The use of ketogenic diet in special situations: Expanding use in intractable epilepsy and other neurologic disorders. Korean J Pediatr 2012;55:316-21. |
| 6. | Lemmon ME, Terao NN, Ng YT, Reisig W, Rubenstein JE, Kossoff EH, et al. Efficacy of the ketogenic diet in lennox-gastaut syndrome: A retrospective review of one institution's experience and summary of the literature. Dev Med Child Neurol 2012;54:464-8. |
| 7. | Thammongkol S, Vears DF, Bicknell-Royle J, Nation J, Draffin K, Stewart KG, et al. Efficacy of the ketogenic diet: Which epilepsies respond? Epilepsia 2012;53:e55-9. |
| 8. | Laffel L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 1999;15:412-26. |
| 9. | Mikkelsen KH, Seifert T, Secher NH, Grøndal T, van Hall G. Systemic, cerebral and skeletal muscle ketone body and energy metabolism during acute hyper-D-β-hydroxybutyratemia in post-absorptive healthy males. J Clin Endocrinol Metab 2015;100:636-43. |
| 10. | Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian J Endocrinol Metab 2016;20:725-9. |
| 11. | Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr 2008;87:44-55. |
| 12. | Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:374-80. |
| 13. | Merra G, Miranda R, Barrucco S, Gualtieri P, Mazza M, Moriconi E, et al. Very-low-calorie ketogenic diet with aminoacid supplement versus very low restricted-calorie diet for preserving muscle mass during weight loss: A pilot double-blind study. Eur Rev Med Pharmacol Sci 2016;20:2613-21. |
| 14. | Hall KD, Chen KY, Guo J, Lam YY, Leibel RL, Mayer LE, et al. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr 2016;104:324-33. |
| 15. | Murata Y, Nishio K, Mochiyama T, Konishi M, Shimada M, Ohta H, et al. Fgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. PLoS One 2013;8:e69330. |
| 16. | Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: Clinical perspectives. Clin Endocrinol (Oxf) 2013;78:489-96. |
| 17. | Cahill GF Jr., Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003;114:149-61. |
| 18. | Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: Review and hypothesis. Nutr Metab (Lond) 2005;2:30. |
| 19. | Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, et al. The failing heart relies on ketone bodies as a fuel. Circulation 2016;133:698-705. |
| 20. | Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A “Thrifty substrate” hypothesis. Diabetes Care 2016;39:1108-14. |
| 21. | Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010;9:3506-14. |
| 22. | Murray AJ, Knight NS, Cole MA, Cochlin LE, Carter E, Tchabanenko K, et al. Novel ketone diet enhances physical and cognitive performance. FASEB J 2016;30:4021-32. |
| 23. | Al-Zaid NS, Dashti HM, Mathew TC, Juggi JS. Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia. Acta Cardiol 2007;62:381-9. |
| 24. | Alessandro R, Gerardo B, Alessandra L, Lorenzo C, Andrea P, Keith G, et al. Effects of twenty days of the ketogenic diet on metabolic and respiratory parameters in healthy subjects. Lung 2015;193:939-45. |
| 25. | Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009;50:304-17. |
| 26. | Kossoff EH. International consensus statement on clinical implementation of the ketogenic diet: Agreement, flexibility, and controversy. Epilepsia 2008;49 Suppl 8:11-3. |
| 27. | Seo JH, Lee YM, Lee JS, Kang HC, Kim HD. Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios – Comparison of 3:1 with 4:1 diet. Epilepsia 2007;48:801-5. |
| 28. | Westman EC, Yancy WS Jr., Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008;5:36. |
| 29. | Hartman AL, Vining EP. Clinical aspects of the ketogenic diet. Epilepsia 2007;48:31-42. |
| 30. | Kossoff EH, McGrogan JR. Worldwide use of the ketogenic diet. Epilepsia 2005;46:280-9. |
| 31. | Stafstrom CE. Dietary approaches to epilepsy treatment: Old and new options on the menu. Epilepsy Curr 2004;4:215-22. |
| 32. | Huttenlocher PR. Ketonemia and seizures: Metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976;10:536-40. |
| 33. | Paoli A, Moro T, Bosco G, Bianco A, Grimaldi KA, Camporesi E, et al. Effects of n-3 polyunsaturated fatty acids (ω-3) supplementation on some cardiovascular risk factors with a ketogenic mediterranean diet. Mar Drugs 2015;13:996-1009. |
| 34. | Alberti KG, Johnston DG, Gill A, Barnes AJ, Orskov H. Hormonal regulation of ketone-body metabolism in man. Biochem Soc Symp 1978;43:163-82. |
| 35. | Nielsen JV, Jönsson E, Nilsson AK. Lasting improvement of hyperglycaemia and bodyweight: Low-carbohydrate diet in type 2 diabetes. A brief report. Ups J Med Sci 2005;110:179-83. |
| 36. | Farrés J, Pujol A, Coma M, Ruiz JL, Naval J, Mas JM, et al. Revealing the molecular relationship between type 2 diabetes and the metabolic changes induced by a very-low-carbohydrate low-fat ketogenic diet. Nutr Metab (Lond) 2010;7:88. |
| 37. | Dashti HM, Mathew TC, Khadada M, Al-Mousawi M, Talib H, Asfar SK, et al. Beneficial effects of ketogenic diet in obese diabetic subjects. Mol Cell Biochem 2007;302:249-56. |
| 38. | Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 2005;142:403-11. |
| 39. | Yancy WS Jr., Foy M, Chalecki AM, Vernon MC, Westman EC. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr Metab (Lond) 2005;2:34. |
| 40. | Gumbiner B, Wendel JA, McDermott MP. Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1996;63:110-5. |
| 41. | Courchesne-Loyer A, Croteau E, Castellano CA, St. Pierre V, Hennebelle M, Cunnane SC, et al. Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab 2017;37:2485-93. |
| 42. | Goday A, Bellido D, Sajoux I, Crujeiras AB, Burguera B, García-Luna PP, et al. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. Nutr Diabetes 2016;6:e230. |
| 43. | Hussain TA, Mathew TC, Dashti AA, Asfar S, Al-Zaid N, Dashti HM, et al. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes. Nutrition 2012;28:1016-21. |
| 44. | Miguelgorry PL, Hendricks EJ. Pharmacotherapy for obesity and changes in eating behavior: A Patient and physician's perspective. Adv Ther 2016;33:1262-6. |
| 45. | Mobbs CV, Mastaitis J, Isoda F, Poplawski M. Treatment of diabetes and diabetic complications with a ketogenic diet. J Child Neurol 2013;28:1009-14. |
| 46. | Lamont BJ, Waters MF, Andrikopoulos S. A low-carbohydrate high-fat diet increases weight gain and does not improve glucose tolerance, insulin secretion or β-cell mass in NZO mice. Nutr Diabetes 2016;6:e194. |
| 47. | Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition 2015;31:1-3. |
| 48. | Dressler A, Reithofer E, Trimmel-Schwahofer P, Klebermasz K, Prayer D, Kasprian G, et al. Type 1 diabetes and epilepsy: Efficacy and safety of the ketogenic diet. Epilepsia 2010;51:1086-9. |
| 49. | Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 2003;88:1617-23. |
| 50. | Paoli A, Canato M, Toniolo L, Bargossi AM, Neri M, Mediati M, et al. The ketogenic diet: An underappreciated therapeutic option?. Clin Ter 2011;162:e145-53. |
| 51. | Gibson AA, Seimon RV, Lee CM, Ayre J, Franklin J, Markovic TP, et al. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes Rev 2015;16:64-76. |
| 52. | Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr 2013;67:759-64. |
| 53. | Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. Low-fat diet for long-term weight loss: A meta-analysis of randomised controlled trials. Br J Nutr 2013;110:1178-87. |
| 54. | Paoli A. Ketogenic diet for obesity: Friend or foe? Int J Environ Res Public Health 2014;11:2092-107. |
| 55. | Castaldo G, Palmieri V, Galdo G, Castaldo L, Molettieri P, Vitale A, et al. Aggressive nutritional strategy in morbid obesity in clinical practice: Safety, feasibility, and effects on metabolic and haemodynamic risk factors. Obes Res Clin Pract 2016;10:169-77. |
| 56. | Dashti HM, Mathew TC, Hussein T, Asfar SK, Behbahani A, Khoursheed MA, et al. Long-term effects of a ketogenic diet in obese patients. Exp Clin Cardiol 2004;9:200-5. |
| 57. | Volek JS, Fernandez ML, Feinman RD, Phinney SD. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 2008;47:307-18. |
| 58. | Yancy WS Jr., Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: A randomized, controlled trial. Ann Intern Med 2004;140:769-77. |
| 59. | Kemper MF, Srivastava S, Todd King M, Clarke K, Veech RL, Pawlosky RJ, et al. An ester of β-hydroxybutyrate regulates cholesterol biosynthesis in rats and a cholesterol biomarker in humans. Lipids 2015;50:1185-93. |
| 60. | Pérez-Guisado J. Ketogenic diets: Additional benefits to the weight loss and unfounded secondary effects. Arch Latinoam Nutr 2008;58:323-9. |
| 61. | Muscogiuri G, Palomba S, Laganà AS, Orio F. Current insights into inositol isoforms, mediterranean and ketogenic diets for polycystic ovary syndrome: From bench to bedside. Curr Pharm Des 2016;22:5554-7. |
| 62. | Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: A pilot study. Nutr Metab (Lond) 2005;2:35. |
| 63. | Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: A position statement of the androgen excess and polycystic ovary syndrome society. Fertil Steril 2009;92:1966-82. |
| 64. | Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ, et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010;94:1812-6. |
| 65. | Nylen K, Likhodii S, Burnham WM. The ketogenic diet: Proposed mechanisms of action. Neurotherapeutics 2009;6:402-5. |
| 66. | Masino SA, Rho JM. Mechanisms of ketogenic diet action. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 4 th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. |
| 67. | Kossoff EH, Hartman AL. Ketogenic diets: New advances for metabolism-based therapies. Curr Opin Neurol 2012;25:173-8. |
| 68. | Danial NN, Hartman AL, Stafstrom CE, Thio LL. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol 2013;28:1027-33. |
| 69. | Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, O'Donnell M, et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 2014;129:426-33. |
| 70. | Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: A review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr 2013;67:789-96. |
| 71. | Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM. Tuberous sclerosis complex and the ketogenic diet. Epilepsia 2005;46:1684-6. |
| 72. | Zhang X, Qin J, Zhao Y, Shi J, Lan R, Gan Y, et al. Long-term ketogenic diet contributes to glycemic control but promotes lipid accumulation and hepatic steatosis in type 2 diabetic mice. Nutr Res 2016;36:349-58. |
| 73. | Caraballo R, Vaccarezza M, Cersósimo R, Rios V, Soraru A, Arroyo H, et al. Long-term follow-up of the ketogenic diet for refractory epilepsy: Multicenter argentinean experience in 216 pediatric patients. Seizure 2011;20:640-5. |
| 74. | Dressler A, Stöcklin B, Reithofer E, Benninger F, Freilinger M, Hauser E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy – The Austrian experience. Seizure 2010;19:404-8. |
| 75. | Moriyama K, Watanabe M, Yamada Y, Shiihara T. Protein-losing enteropathy as a rare complication of the ketogenic diet. Pediatr Neurol 2015;52:526-8. |
| 76. | Kanikarla-Marie P, Jain SK. Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. Free Radic Biol Med 2016;95:268-77. |
| 77. | Ellenbroek JH, van Dijck L, Töns HA, Rabelink TJ, Carlotti F, Ballieux BE, et al. Long-term ketogenic diet causes glucose intolerance and reduced β- and α-cell mass but no weight loss in mice. Am J Physiol Endocrinol Metab 2014;306:E552-8. |
| 78. | Bielohuby M, Matsuura M, Herbach N, Kienzle E, Slawik M, Hoeflich A, et al. Short-term exposure to low-carbohydrate, high-fat diets induces low bone mineral density and reduces bone formation in rats. J Bone Miner Res 2010;25:275-84. |
| 79. | Liśkiewicz AD, Kasprowska D, Wojakowska A, Polański K, Lewin-Kowalik J, Kotulska K, et al. Long-term high fat ketogenic diet promotes renal tumor growth in a rat model of tuberous sclerosis. Sci Rep 2016;6:21807. |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]
| This article has been cited by | | 1 |
Dietary patterns and cardiometabolic health: Clinical evidence and mechanism |
|
| Wenting Wang, Yanfei Liu, Yiwen Li, Binyu Luo, Zhixiu Lin, Keji Chen, Yue Liu | | MedComm. 2023; 4(1) | | [Pubmed] | [DOI] | | | 2 |
A bibliometric analysis of the global trends and hotspots for the ketogenic diet based on CiteSpace |
|
| Ran Ye, Yanfei Cheng, Yingying Ge, Guihua Xu, Wenjing Tu | | Medicine. 2023; 102(5): e32794 | | [Pubmed] | [DOI] | | | 3 |
Clinical Considerations and Practical Advice for People Living With Type 2 Diabetes Who Undertake Regular Exercise or Aim to Exercise Competitively |
|
| Sam N. Scott, Charlotte Hayes, Thomas Zeuger, Andrew P. Davies, Rob C. Andrews, Matthew Cocks | | Diabetes Spectrum. 2023; 36(2): 114 | | [Pubmed] | [DOI] | | | 4 |
Feeding the gut microbiome: impact on multiple sclerosis |
|
| Matteo Bronzini, Alessandro Maglione, Rachele Rosso, Manuela Matta, Federica Masuzzo, Simona Rolla, Marinella Clerico | | Frontiers in Immunology. 2023; 14 | | [Pubmed] | [DOI] | | | 5 |
Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis |
|
| Sabine Kleissl-Muir, Bodil Rasmussen, Alice Owen, Caryn Zinn, Andrea Driscoll | | Frontiers in Nutrition. 2022; 9 | | [Pubmed] | [DOI] | | | 6 |
Ketogenic Diet Benefits to Weight Loss, Glycemic Control, and Lipid Profiles in Overweight Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trails |
|
| Chong Zhou, Meng Wang, Jiling Liang, Guomin He, Ning Chen | | International Journal of Environmental Research and Public Health. 2022; 19(16): 10429 | | [Pubmed] | [DOI] | | | 7 |
ß-hydroxybutyrate reduces blastocyst viability via trophectoderm-mediated metabolic aberrations in mice |
|
| Emma G Whatley, Thi T Truong, Dagmar Wilhelm, Alexandra J Harvey, David K Gardner | | Human Reproduction. 2022; | | [Pubmed] | [DOI] | | | 8 |
Controlling carbohydrate content in antiepileptic medications for children on a ketogenic diet |
|
| Silvia Martín Prado, Maite Pozas del Río, Elvira Cañedo Villarroya, Consuelo Pedrón Giner | | Nutrición Hospitalaria. 2022; | | [Pubmed] | [DOI] | | | 9 |
Ketogenic Diet: A Promising Neuroprotective Composition for
Managing Alzheimer’s Diseases and its Pathological Mechanisms |
|
| Badrinathan Sridharan, Meng-Jen Lee | | Current Molecular Medicine. 2022; 22(7): 640 | | [Pubmed] | [DOI] | | | 10 |
Potentials of ketogenic diet against chronic kidney diseases: pharmacological insights and therapeutic prospects |
|
| Sushmita Kundu, Khandkar Shaharina Hossain, Akhi Moni, Md. Sarwar Zahan, Md. Masudur Rahman, Md Jamal Uddin | | Molecular Biology Reports. 2022; | | [Pubmed] | [DOI] | | | 11 |
Surveillance and dietary risk assessment of endocrine-disrupting pesticides in eggplant/brinjal and cauliflower in Pakistan |
|
| Farwa Talat, Hina Aslam, Karam Ahad, Nazia Rafique | | Environmental Science and Pollution Research. 2022; | | [Pubmed] | [DOI] | | | 12 |
Low-Carbohydrate High-Fat Diet: A SWOC Analysis |
|
| Dena Nuwaylati, Basmah Eldakhakhny, Abdulhadi Bima, Hussein Sakr, Ayman Elsamanoudy | | Metabolites. 2022; 12(11): 1126 | | [Pubmed] | [DOI] | | | 13 |
Alleviation of Dyslipidemia via a Traditional Balanced Korean Diet Represented by a Low Glycemic and Low Cholesterol Diet in Obese Women in a Randomized Controlled Trial |
|
| Min Jung Kim, Sunmin Park, Hye Jeong Yang, Phil-Kyung Shin, Haeng Jeon Hur, Seon-Joo Park, Kyun-Hee Lee, Moonju Hong, Jin Hee Kim, Sang-Woon Choi, Hae-Jeung Lee, Myung-Sunny Kim | | Nutrients. 2022; 14(2): 235 | | [Pubmed] | [DOI] | | | 14 |
Very Low-Calorie Ketogenic Diet: A Potential Application in the Treatment of Hypercortisolism Comorbidities |
|
| Valentina Guarnotta, Fabrizio Emanuele, Roberta Amodei, Carla Giordano | | Nutrients. 2022; 14(12): 2388 | | [Pubmed] | [DOI] | | | 15 |
Impact of a Very Low-Calorie Ketogenic Diet (VLCKD) on Changes in Handgrip Strength in Women with Obesity |
|
| Luigi Barrea, Giulia de Alteriis, Giovanna Muscogiuri, Claudia Vetrani, Ludovica Verde, Elisabetta Camajani, Sara Aprano, Annamaria Colao, Silvia Savastano | | Nutrients. 2022; 14(19): 4213 | | [Pubmed] | [DOI] | | | 16 |
The Role of Ketogenic Diet in the Treatment of Neurological Diseases |
|
| Damian Dynka, Katarzyna Kowalcze, Agnieszka Paziewska | | Nutrients. 2022; 14(23): 5003 | | [Pubmed] | [DOI] | | | 17 |
Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders |
|
| Valentina Spigoni, Gloria Cinquegrani, Nicolas Thomas Iannozzi, Giulia Frigeri, Giulia Maggiolo, Marta Maggi, Vanessa Parello, Alessandra Dei Cas | | Frontiers in Endocrinology. 2022; 13 | | [Pubmed] | [DOI] | | | 18 |
Therapeutic Indications of the Ketogenic Diet: A Integrative Review |
|
| Natália Cíntia de Oliveira, Gleice Kelly de Sousa, Durval Ribas Filho | | MedNEXT Journal of Medical and Health Sciences. 2021; 2(3) | | [Pubmed] | [DOI] | | | 19 |
Metabolic Derangement in Pediatric Patient with Obesity: The Role of Ketogenic Diet as Therapeutic Tool |
|
| Valeria Calcaterra, Elvira Verduci, Martina Chiara Pascuzzi, Vittoria Carlotta Magenes, Giulia Fiore, Elisabetta Di Profio, Elisavietta Tenuta, Alessandra Bosetti, Carolina Federica Todisco, Enza D’Auria, Gianvincenzo Zuccotti | | Nutrients. 2021; 13(8): 2805 | | [Pubmed] | [DOI] | | | 20 |
Hypocaloric Dieting Unsettles the Neuroenergetic Homeostasis in Humans |
|
| Ewelina K. Wardzinski, Carolin Hyzy, Kai Uwe Duysen, Uwe H. Melchert, Kamila Jauch-Chara, Kerstin M. Oltmanns | | Nutrients. 2021; 13(10): 3433 | | [Pubmed] | [DOI] | | | 21 |
Sex-specific effects of ketogenic diet after pre-exposure to a high-fat, high-sugar diet in rats |
|
| Elizabeth Sahagun, Brent B. Bachman, Kimberly P. Kinzig | | Nutrition, Metabolism and Cardiovascular Diseases. 2021; 31(3): 961 | | [Pubmed] | [DOI] | | | 22 |
Intérêts et limites de la diète cétogène |
|
| Dominique Vincent | | Pratiques en nutrition. 2021; 17(65): 10 | | [Pubmed] | [DOI] | | | 23 |
Ketogenic therapies in mild cognitive impairment and dementia |
|
| Héléne T. Cronjé, Majken K. Jensen, Maarten P. Rozing, Manja Koch | | Current Opinion in Lipidology. 2021; 32(5): 330 | | [Pubmed] | [DOI] | | | 24 |
Severe ketoacidosis in a lactating woman on a ketogenic diet |
|
| Mona Alsomali | | Internal Medicine Journal. 2021; 51(1): 144 | | [Pubmed] | [DOI] | | | 25 |
Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open-label, parallel-group, controlled pilot trial |
|
| Jian Li, Wen-Pei Bai, Bo Jiang, Le-Ran Bai, Bei Gu, Shu-Xiang Yan, Fu-Ying Li, Bin Huang | | Journal of Obstetrics and Gynaecology Research. 2021; 47(3): 1145 | | [Pubmed] | [DOI] | | | 26 |
Carbohydrates to Prevent and Treat Obesity in a Murine Model of Diet-Induced Obesity |
|
| Ellen Vercalsteren, Christine Vranckx, Katrien Corbeels, Bart Van der Schueren, Greetje Vande Velde, Roger Lijnen, Ilse Scroyen | | Obesity Facts. 2021; 14(4): 370 | | [Pubmed] | [DOI] | | | 27 |
Dietary Interventions: A Promising Treatment for Polycystic Ovary Syndrome |
|
| Xuan Che, Zhuo Chen, Mingqi Liu, Zhongcheng Mo | | Annals of Nutrition and Metabolism. 2021; 77(6): 313 | | [Pubmed] | [DOI] | | | 28 |
The effect of ketogenic diet on serum lipid concentrations in children with medication resistant epilepsy |
|
| Ünsal Yilmaz, Selvinaz Edizer, Melis Köse, Zeynep Akisin, Yigithan Güzin, Serdar Pekuz, Hatice Hilal Kirkgöz, Merve Yavuz, Aycan Ünalp | | Seizure. 2021; 91: 99 | | [Pubmed] | [DOI] | | | 29 |
Sex-specific genetic architecture in response to American and ketogenic diets |
|
| Anna C. Salvador, Danny Arends, William T. Barrington, Ahmed M. Elsaadi, Gudrun A. Brockmann, David W. Threadgill | | International Journal of Obesity. 2021; 45(6): 1284 | | [Pubmed] | [DOI] | | | 30 |
The ketogenic diet: history, mechanism of action, indications and contraindications |
|
| E. V. Ivannikova, M. A. Altashina, E. A. Troshina | | Problems of Endocrinology. 2021; 68(1): 49 | | [Pubmed] | [DOI] | | | 31 |
The effect of long-term ketogenic diet on serum adiponectin and insulin-like growth factor-1 levels in mice |
|
| Deandra M. Widiatmaja, Alif Lutvyani, Desi R. Sari, Hamidah Kurniasari, Ismi D. Meiliana, Minidian Fasitasari, Yoshio Yamaoka, Purwo S. Rejeki | | Journal of Basic and Clinical Physiology and Pharmacology. 2021; 0(0) | | [Pubmed] | [DOI] | | | 32 |
Microecological preparation combined with an modified low-carbon diet improves glucolipid metabolism and cardiovascular complication in obese patients |
|
| Jianguo Liu, Liehui Xiao, Hezhongrong Nie, Yong Pan, Yan Liu, Zhentian Zhang, Xiuping Lin, Yuan Zhang, Jinchuang Cai, Muxiu Yang, Yajing Liu, Leijun Zhang, Aimin Xu, Cuifeng Zhu | | Diabetology & Metabolic Syndrome. 2021; 13(1) | | [Pubmed] | [DOI] | | | 33 |
The Ginsenoside Exhibits Antiosteoporosis Effects in Ketogenic-Diet-Induced Osteoporosis via Rebalancing Bone Turnover |
|
| Qi Liu, Jian Zhou, Zhou Yang, Chuhai Xie, Yan Huang, Long Ling, Yanming Cao, Hailan Hu, Yue Hua | | Frontiers in Pharmacology. 2021; 11 | | [Pubmed] | [DOI] | | | 34 |
Effects of Mixed of a Ketogenic Diet in Overweight and Obese Women with Polycystic Ovary Syndrome |
|
| Raffaele Ivan Cincione, Francesca Losavio, Fabiana Ciolli, Anna Valenzano, Giuseppe Cibelli, Giovanni Messina, Rita Polito | | International Journal of Environmental Research and Public Health. 2021; 18(23): 12490 | | [Pubmed] | [DOI] | | | 35 |
The Ketogenic Diet Revisited: Beyond Ketones |
|
| Jo Sourbron, Karin Thevissen, Lieven Lagae | | Frontiers in Neurology. 2021; 12 | | [Pubmed] | [DOI] | | | 36 |
Popüler Diyet Akimlarinin Vücut Agirligi ve Saglik Üzerine Etkileri |
|
| Sefa Can KÜÇÜK, Artun YIBAR | | Akademik Gida. 2021; : 98 | | [Pubmed] | [DOI] | | | 37 |
Dieta cetogénica como alternativa en el tratamiento de la obesidad |
|
| Roberto Carlos Pérez Kast, Hannia Deni Castro Cortez, Areli Lozano Tavares, Andrea Arreguín Coronado, Vania Urías Orona, Heriberto Castro García | | RESPYN Revista Salud Pública y Nutrición. 2021; 20(3): 46 | | [Pubmed] | [DOI] | | | 38 |
Alternatives to Insulin for the Regulation of Blood Sugar Levels in Type 2 Diabetes |
|
| Stephen C. Bondy, Meixia Wu, Kedar N. Prasad | | International Journal of Molecular Sciences. 2020; 21(21): 8302 | | [Pubmed] | [DOI] | | | 39 |
Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index |
|
| Erwin Garcia, Irina Shalaurova, Steven P. Matyus, David N. Oskardmay, James D. Otvos, Robin P.F. Dullaart, Margery A. Connelly | | Journal of Clinical Medicine. 2020; 9(2): 321 | | [Pubmed] | [DOI] | | | 40 |
A Case of Hypoglycemia Associated With the Ketogenic Diet and Alcohol Use |
|
| Christopher Spoke, Samar Malaeb | | Journal of the Endocrine Society. 2020; 4(6) | | [Pubmed] | [DOI] | | | 41 |
Ketogenic Diet Ameliorates Cardiac Dysfunction via Balancing Mitochondrial Dynamics and Inhibiting Apoptosis in Type 2 Diabetic Mice |
|
| Yongzheng Guo, Cheng Zhang, Fei-Fei Shang, Minghao Luo, Yuehua You, Qiming Zhai, Yong Xia, Luo Suxin | | Aging and disease. 2020; 11(2): 229 | | [Pubmed] | [DOI] | | | 42 |
Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought? |
|
| Gerwyn Morris, Basant K Puri, Andre Carvalho, Michael Maes, Michael Berk, Anu Ruusunen, Lisa Olive | | International Journal of Neuropsychopharmacology. 2020; 23(6): 366 | | [Pubmed] | [DOI] | | | 43 |
Is the Ketogenic Diet an Effective and Safe Approach to Type 2 Diabetes Management and Weight Loss? |
|
| Deep Dutta, Soumitra Ghosh, Sanjay Kalra, Indira Maisnam, Meha Sharma | | US Endocrinology. 2020; 16(1): 15 | | [Pubmed] | [DOI] | | | 44 |
Ketogenic Diet as a Trigger for Diabetic Ketoacidosis in a Misdiagnosis of Diabetes: A Case Report |
|
| Alexander J. White-Cotsmire, Amber M. Healy | | Clinical Diabetes. 2020; 38(3): 318 | | [Pubmed] | [DOI] | | | 45 |
Could ketogenic diet “starve” cancer? Emerging evidence |
|
| Luigi Barrea, Massimiliano Caprio, Dario Tuccinardi, Eleonora Moriconi, Laura Di Renzo, Giovanna Muscogiuri, Annamaria Colao, Silvia Savastano | | Critical Reviews in Food Science and Nutrition. 2020; : 1 | | [Pubmed] | [DOI] | | | 46 |
Application of nutrient essentiality criteria to dietary carbohydrates |
|
| Justin Tondt, William S. Yancy, Eric C. Westman | | Nutrition Research Reviews. 2020; 33(2): 260 | | [Pubmed] | [DOI] | | | 47 |
Efficacy of the ketogenic diet in patients with Dravet syndrome: A meta-analysis |
|
| Yan-Qiu Wang, Zhi-Xu Fang, Yi-Wei Zhang, Ling-Ling Xie, Li Jiang | | Seizure. 2020; 81: 36 | | [Pubmed] | [DOI] | | | 48 |
Ketogenic diet attenuates aging-associated myocardial remodeling and dysfunction in mice |
|
| Yunhua Yu, Fei Wang, Jianjun Wang, Dongmei Zhang, Xianxian Zhao | | Experimental Gerontology. 2020; 140: 111058 | | [Pubmed] | [DOI] | | | 49 |
Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study |
|
| Mikiko Watanabe, Renata Risi, Elisabetta Camajani, Savina Contini, Agnese Persichetti, Dario Tuccinardi, Ilaria Ernesti, Stefania Mariani, Carla Lubrano, Alfredo Genco, Giovanni Spera, Lucio Gnessi, Sabrina Basciani | | Nutrients. 2020; 12(7): 2141 | | [Pubmed] | [DOI] | | | 50 |
Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report |
|
| Matthew Earle, Brian Ault, Caitlin Bonney | | Clinical Practice and Cases in Emergency Medicine. 2020; 4(2): 185 | | [Pubmed] | [DOI] | | | 51 |
Keto microbiota: A powerful contributor to host disease recovery |
|
| Amanda Cabrera-Mulero, Alberto Tinahones, Borja Bandera, Isabel Moreno-Indias, Manuel Macías-González, Francisco J. Tinahones | | Reviews in Endocrine and Metabolic Disorders. 2019; 20(4): 415 | | [Pubmed] | [DOI] | | | 52 |
Short-term and long-term ketogenic diet therapy and the addition of exercise have differential impacts on metabolic gene expression in the mouse energy-consuming organs heart and skeletal muscle |
|
| Kozue Shimizu, Hazuki Saito, Kanako Sumi, Yuri Sakamoto, Yoichi Tachi, Kaoruko Iida | | Nutrition Research. 2018; 60: 77 | | [Pubmed] | [DOI] | | | 53 |
Imaging the Effects of ß-Hydroxybutyrate on Peri-Infarct Neurovascular Function and Metabolism |
|
| Paolo Bazzigaluppi, Evelyn M. Lake, Tina L. Beckett, Margaret M. Koletar, Iliya Weisspapir, Stefan Heinen, James Mester, Aaron Lai, Rafal Janik, Adrienne Dorr, JoAnne McLaurin, Greg J. Stanisz, Peter L. Carlen, Bojana Stefanovic | | Stroke. 2018; 49(9): 2173 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
